Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids

Biomaterials

Volumn 34, Issue 11, 2013, Pages 2773-2786

  Mo, Ran ^a   Sun, Qiong ^a   Li, Nan ^a   Zhang, Can ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antitumor efficacy; Drug delivery; Liposomes; PH sensitivity; Zwitterionic oligopeptide lipid

Indexed keywords

ANTI-CANCER DRUG DELIVERY; ANTI-PROLIFERATIVE; ANTI-TUMOR ACTIVITIES; ANTI-TUMOR EFFICACY; ANTICANCER DRUG; ANTITUMOR EFFECT; APOPTOTIC; CANCER THERAPY; CELLULAR UPTAKE; IN-VIVO; INHIBITORY CONCENTRATION; INTRACELLULAR DELIVERY; INTRAVENOUS ADMINISTRATION; OLIGOPEPTIDES; PH RESPONSE; PH SENSITIVE; PH-SENSITIVE LIPOSOMES; PH-SENSITIVITY; POSITIVE CHARGES; PROTON SPONGE; RENAL CARCINOMA; TUMOR MODELS;

AMINO ACIDS; BIOCHEMISTRY; CELL DEATH; DRUG DELIVERY; LIPIDS; LIPOSOMES; MOLECULAR BIOLOGY; POLYPEPTIDES; TUMORS; ZETA POTENTIAL;

PH EFFECTS;

1,5 DIOCTADECYL GLUTAMYL 2 HISTIDYL HEXAHYDROBENZOIC ACID; 1,5 DISTEARYL N (N ALPHA (4 METHOXY POLYETHYLENE GYCOL 2000) BUTANEDIONE)HISTIDYL GLUTAMATE; ANTINEOPLASTIC AGENT; COUMARIN; LIPOSOME; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYSOSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRION; MOUSE; NANOENCAPSULATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; LIPOSOMES; MALE; MICE; MITOCHONDRIA; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TUMOR MICROENVIRONMENT;

EID: 84873081065     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.030     Document Type: Article

References (49)

1. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
2. Wang H., Zhao P., Liang X., Gong X., Song T., Niu R., et al. Folate-PEG coated cationic modified chitosan-cholesterol liposomes for tumor-targeted drug delivery. Biomaterials 2010, 31:4129-4138.
3. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
4. ®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
5. Fassas A., Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005, 46:795-802.
6. Narang A.S., Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 2011, 63:640-658.
7. Un K., Sakai-Kato K., Oshima Y., Kawanishi T., Okuda H. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials 2012, 33:8131-8141.
8. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
9. Zohra F.T., Chowdhury E.H., Akaike T. High performance mRNA transfection through carbonate apatite-cationic liposome conjugates. Biomaterials 2009, 30:4006-4013.
10. Koynova R., Wang L., MacDonald R.C. An intracellular lamellar-nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proc Natl Acad Sci U S A 2006, 103:14373-14378.
11. Yamada Y., Harashima H. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials 2012, 33:1589-1595.
12. Chan C.L., Majzoub R.N., Shirazi R.S., Ewert K.K., Chen Y.J., Liang K.S., et al. Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid. Biomaterials 2012, 33:4928-4935.
13. Shigeta K., Kawakami S., Higuchi Y., Okuda T., Yagi H., Yamashita F., et al. Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J Control Release 2007, 118:262-270.
14. Dehshahri A., Oskuee R.K., Shier W.T., Hatefi A., Ramezani M. Gene transfer efficiency of high primary amine content, hydrophobic, alkyl-oligoamine derivatives of polyethylenimine. Biomaterials 2009, 30:4187-4194.
15. Soenen S.J., Brisson A.R., De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009, 30:3691-3701.
16. Moore N.M., Barbour T.R., Sakiyama-Elbert S.E. Synthesis and characterization of four-arm poly(ethylene glycol)-based gene delivery vehicles coupled to integrin and DNA-binding peptides. Mol Pharm 2008, 5:140-150.
17. Rodrigues P.C., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C., et al. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg Med Chem 1999, 7:2517-2524.
18. Sawant R.M., Hurley J.P., Salmaso S., Kale A., Tolcheva E., Levchenko T.S., et al. " SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 2006, 17:943-949.
19. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
20. Obata Y., Tajima S., Takeoka S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J Control Release 2010, 142:267-276.
21. Mo R., Sun Q., Xue J., Li N., Li W., Zhang C., et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv Mater 2012, 24:3659-3665.
22. Perry J.W., Wobus C.E. Endocytosis of murine norovirus 1 into murine macrophages is dependent on dynamin II and cholesterol. J Virol 2010, 84:6163-6176.
23. Durymanov M.O., Beletkaia E.A., Ulasov A.V., Khramtsov Y.V., Trusov G.A., Rodichenko N.S., et al. Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1. J Control Release 2012, 163:211-219.
24. Koivusalo M., Welch C., Hayashi H., Scott C.C., Kim M., Alexander T., et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J Cell Biol 2010, 188:547-563.
25. Kommareddy S., Amiji M. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine 2007, 3:32-42.
26. Choi K.Y., Min K.H., Yoon H.Y., Kim K., Park J.H., Kwon I.C., et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011, 32:1880-1889.
27. Kohli E., Han H.Y., Zeman A.D., Vinogradov S.V. Formulations of biodegradable nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J Control Release 2007, 121:19-27.
28. Oumzil K., Khiati S., Grinstaff M.W., Barthélémy P. Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating. J Control Release 2011, 151:123-130.
29. Li S.D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010, 145:178-181.
30. Xu P., Van Kirk E.A., Zhan Y., Murdoch W.J., Radosz M., Shen Y. Targeted charge-reversal nanoparticles for nuclear drug delivery. Angew Chem Int Ed Engl 2007, 46:4999-5002.
31. Lee Y., Ishii T., Cabral H., Kim H.J., Seo J.H., Nishiyama N., et al. Charge-conversional polyionic complex micelles-efficient nanocarriers for protein delivery into cytoplasm. Angew Chem Int Ed Engl 2009, 48:5309-5312.
32. Yue Z.G., Wei W., Lv P.P., Yue H., Wang L.Y., Su Z.G., et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules 2011, 12:2440-2446.
33. Koren E., Apte A., Jani A., Torchilin V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 2012, 160:264-273.
34. Nie Y., Günther M., Gu Z., Wagner E. Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding. Biomaterials 2011, 32:858-869.
35. Khalil I.A., Kogure K., Futaki S., Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006, 281:3544-3551.
36. Yamada Y., Furukawa R., Yasuzaki Y., Harashima H. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol Ther 2011, 19:1449-1456.
37. Midoux P., Pichon C., Yaouanc J.J., Jaffrès P.A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009, 157:166-178.
38. Lee E.S., Na K., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett 2005, 5:325-329.
39. Wen Y., Guo Z., Du Z., Fang R., Wu H., Zeng X., et al. Serum tolerance and endosomal escape capacity of histidine-modified pDNA-loaded complexes based on polyamidoamine dendrimer derivatives. Biomaterials 2012, 33:8111-8121.
40. Wang X.X., Li Y.B., Yao H.J., Ju R.J., Zhang Y., Li R.J., et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011, 32:5673-5687.
41. Zhang L., Yao H.J., Yu Y., Zhang Y., Li R.J., Ju R.J., et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012, 33:565-582.
42. Biswas S., Dodwadkar N.S., Deshpande P.P., Torchilin V.P. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release 2012, 159:393-402.
43. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
44. Biasutto L., Dong L.F., Zoratti M., Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion 2010, 10:670-681.
45. Wenner C.E. Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol 2012, 227:450-456.
46. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178-194.
47. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525-537.
48. Desai B.N., Myers B.R., Schreiber S.L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci U S A 2002, 99:4319-4324.
49. Ramanathan A., Schreiber S.L. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A 2009, 106:22229-22232.